Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
AbbVie Inc.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
Signals scattered
Get notified when we ship meaningful updates. No spam, no daily noise.
2 of 5 met · composite in line with peers
Business quality, valuation against the sector, and position in the 52-week range — whether they line up or not.
Strong fundamentals
Profitability
3/4
Debt & liquidity
3/3
Efficiency
2/2
Capital returns at AbbVie Inc. run well ahead of the sector: ROE reaches 15,367.3%, +57,603% above the sector median of 26.6%, and ROIC of 17.3% sits +49% above the median — figures that reflect a business extracting real returns from its asset base. FCF grew 2.1% year over year, outpacing the sector median of -7.7% by +127%, and the F-Score of 8/9 confirms that the balance sheet is tightening in the right direction. The price paid for those returns is not modest: a P/E of 75.1× runs +143% above the sector median of 30.9×, and the current ratio of 0.67 trails the sector median of 1.40 by -52%, leaving near-term liquidity as the clearest structural gap. Consensus and the realized three-year EPS CAGR of {{value:eps_cagr_3y}} are broadly aligned — an unusual condition — though the beat rate over eight quarters has been weak, so the track record of clearing estimates is thinner than the headline quality numbers suggest.
| Ticker | Name | F-Score | ROE | Revenue YoY | Op. margin |
|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | 8/9 | 15 367% | +9% |
Quarter-by-quarter classification · a retrospective read by the current logic · not a price forecast
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice. The method did not see these quarters in real time; this is the current logic applied to past reports.
The market prices in earnings growth; analyst sentiment is strengthening; has mostly beaten consensus.
Price against next year's expected earnings. The forward P/E already carries analyst optimism — read it alongside the “Versus consensus” line.
A forward P/E below the current one means the market expects earnings to grow; above it, to fall. The historical growth is realized figures from SEC filings, not a forecast.
The three-month change in the share of positive analyst ratings. This is sentiment, not an earnings-estimate revision, and not a call to act.
When AbbVie reports on 2026-10-29, track revenue year over year and free cash flow growth, which currently sits 127% above the sector median. Also check whether the profitability F-Score holds at 3/4 or improves, particularly the gross margin signal.
AbbVie's current ratio is 52% below the sector median of 1.40, a liquidity gap worth understanding in context. In the annual report, find management's discussion of debt obligations and how the company plans to manage near-term liabilities against its strong ROIC of 11.6%.
Pick two or three names from the Health Care table in section 06 and line up one metric — P/E, ROIC, or current ratio — against AbbVie's figures. The table is alphabetical with no ranking, so the comparison is yours to frame without any implied ordering.
Steps you can check yourself, based on the figures in this brief.
Piotroski F-Score: nine binary tests of financial strength from the annual report. A ✓ marks a test passed, a dot (·) a test failed.
Over 4 years: +10%-9%-19%-0%
Over 4 years: 3.344.396.754.07
Over 4 years: +3%-6%+4%+9%
The context on the right shows how each figure compares with the sector median. The trend below tracks the change over recent fiscal years.
Beat consensus in 7 of 8 recent quarters — the company clears estimates regularly (consensus is often set conservatively).
Last quarter's EPS against consensus, plus the estimated date of the next report.
| 25% |
| ABT | Abbott | 6/9 | 13% | +6% | 18% |
| AMGN | Amgen | 7/9 | 106% | +10% | 25% |
| BMY | Bristol-Myers Squibb | 8/9 | 41% | -0% | — |
| CVS | CVS Health | 6/9 | 2% | +8% | 1% |
| DHR | Danaher | 5/9 | 7% | +3% | 19% |
| GILD | Gilead Sciences | 8/9 | 40% | +2% | 34% |
| ISRG | Intuitive Surgical | 6/9 | 17% | +21% | 29% |
| JNJ | Johnson & Johnson | 4/9 | 35% | +6% | — |
| LLY | Eli Lilly | 7/9 | 101% | +45% | — |
| MRK | Merck | 4/9 | 37% | +1% | — |
| PFE | Pfizer | 5/9 | 9% | -2% | — |
| TMO | Thermo Fisher | 5/9 | 13% | +4% | 17% |
| UNH | UnitedHealth | 7/9 | 18% | +12% | 4% |
A sample of 14 companies in the sector including the target, alphabetical, unranked. Data from the latest SEC annual reports.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
A simplified retrospective read: no analyst forecast (not available historically); the source is the annual report as of the date, so neighbouring quarters can rest on the same data. Quarters with the same classification in a row are merged into one row — each row is one change in the read, not a separate quarter. One ticker is an illustration of the classification logic, not statistics. How we calculate →
The last few quarters are recent context, not a fixed rate. Consensus for near quarters is set low, so companies clear it routinely; over long horizons the forecasts run the other way, too high.
A description of what the market and analysts expect. Not a price forecast and not investment advice. Analyst forecasts run systematically optimistic over long horizons — read them with that discount.